Recalls of Overweight Tablets Reflects Knowledge Gap in Industry on Tablet Making; Solutions Offered
This article was originally published in The Gold Sheet
Executive Summary
The high number of drug product recalls over the past few years for overweight tablets can be attributed to a poor understanding in the pharmaceutical industry on how tablets are made.
You may also be interested in...
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: